Wegovy 1.7 mg: Injectable solution for sustainable weight loss

What is Wegovy 1.7 mg

Wegovy 1.7 mg is a pre-filled pen injectable solution used for the management of overweight and obesity in adults. Its active ingredient, semaglutide, acts as an agonist of the GLP-1 receptor, a natural hormone that regulates satiety and reduces appetite. It helps reduce calorie intake while stabilizing blood glucose levels.

Clinical studies conducted by Novo Nordisk show an average weight loss of 15% after 68 weeks of use, combined with a balanced diet and regular physical activity.

Wegovy 1.7 mg price and purchase conditions

Wegovy 1.7 mg is available in pharmacies between €230 and €270 According to the supplier. This medication is only available by prescription. In France, it is not yet covered by national health insurance, but some private health insurance companies offer partial reimbursement.
Each pre-filled pen contains 3 ml of injectable solution, equivalent to four weekly doses.

Factors influencing the price:

Prescribed dosage and duration of treatment.
Place of purchase (physical pharmacy or online).
Financial assistance or programs from the manufacturer.

Side effect of Wegovy 1.7 mg

The side effects of Wegovy 1.7 mg are generally mild and decrease over time.
The most common ones are:

Nausea and vomiting.
Abdominal pain.
Constipation or diarrhea.
Headache.

Less common side effects may include pancreatitis, diabetic retinopathy, or a slight increase in heart rate

Adequate hydration helps to limit dehydration associated with gastrointestinal disorders.

INSTRUCTIONS FOR USE

Wegovy is injected once a week, on the same day, subcutaneously in the thigh, abdomen, or upper arm. The 1.7 mg dose is the penultimate step before the 2.4 mg maintenance dose. It is essential to follow the prescribed protocol to avoid side effects.